Mobile

Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade and dexamethasone in patients with multiple myeloma

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-022515-20

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase I  To determine the maximum tolerated dose (MTD) and RP2D of PD 0332991 in combination with bortezomib and dexamethasone Phase II  To evaluate the anti-tumor activity of PD 0332991 in combination with bortezomib and dexamethasone based on ORR as defined by IMWGURC 9

Critère d'inclusion

  • Refractory Multiple Myeloma

Liens